- Login
- Register & Subscribe
- Language: EN FR DE
Company News
SkyePharma sees higher 2010 sales, installs new CEO
Thursday 19 August 2010
Building on momentum in the first-half year, SkyePharma Plc said it expects to report an increase in revenue for 2010. Driving the business forward will be the new CEO, Axel Müller, who takes over the top job from Ken Cunningham on 23 August.
Location
United Kingdom
See map: Google Maps
Regulatory review of gene therapy on schedule
Wednesday 18 August 2010
The European regulatory review of a ground-breaking gene therapy for the treatment of a protein deficiency linked to pancreatitis is on schedule with a decision expected by mid-2011, according to the developer, Amsterdam Molecular Therapeutics (AMT).
Location
Netherlands
See map: Google Maps
Intercell’s Q2 results deteriorate despite higher product sales
Wednesday 18 August 2010
Intercell AG, the Austrian maker of vaccines for the prevention and treatment of disease, reported a 35.2% decline in revenue to €9.7 million for the second 2010 quarter, mainly due to the absence of milestone receipts from its collaborations.
Location
Austria
Crucell’s second 2010 quarter revenues set a record
Tuesday 17 August 2010
Total revenues and other operating income of Crucell NV rose by 63% to a record €128.6 million in the second 2010 quarter, mainly due to booming sales of Quinvaxem in the developing world.
Location
Netherlands
See map: Google Maps
Lilly halts development of Alzheimer’s drug
Tuesday 17 August 2010
Eli Lilly and Company said it is stopping development of semagacestat for Alzheimer’s disease after preliminary data from two Phase 3 studies showed the compound did not slow disease progression and was associated with an increased risk of skin cancer.
Location
United States
See map: Google Maps
Lundbeck increases profit by 30% in Q2
Sunday 15 August 2010
H. Lundbeck A/S said its profit before interest and tax (EBIT) increased by 30% to DKK 936 million (€125.6 million) in the 2010 second quarter on revenue of DKK 3.8 billion, up by 6.8%. It expects revenue of DKK 14.3 to 14.8 billion for the year.
Location
Denmark
Pronova’s revenue and profit drop in Q2
Sunday 15 August 2010
Pronova BioPharma ASA, the Norwegian producer of omega-3 derived prescription products, posted a 2.6% decline in revenue in the second 2010 quarter to NOK 443.6 million (€55.9 million) and a 59% drop in net profit to NOK 51.7 million.
Location
Norway
Algeta advances its radiopharmaceutical
Friday 13 August 2010
Algeta ASA is increasing manufacturing capacity for its lead product, a radiopharmaceutical, as recruitment continues in a pivotal Phase 3 trial of the product in patients with bone metastases arising from hormone-refractory prostate cancer.
Location
Norway
Evotec reports first-half operating profit, appoints new CFO
Thursday 12 August 2010
Evotec AG has reported a small operating profit for the 2010 first half – the first in its 17-year history. The profit, amounting to €0.3 million compared with a year-earlier loss of €29.1 million, comes a little more than a year into a major restructuring programme.
Location
Germany
See map: Google Maps
4SC gives clinical update
Wednesday 11 August 2010
4SC AG expects to report data for its lead investigational compound, vidofludimus, in separate Phase 2 studies in inflammatory bowel disease and rheumatoid arthritis by the end of 2010. On 30 June, the German company had cash of €26.5 million.
Location
Germany
See map: Google Maps
Select a News Category
Recent Appointments
Tim Edwards elected chairman of BIA
Tuesday September 7 2010
Index Ventures appoints antibody expert as partner
Friday September 3 2010
Colin Stewart appointed CEO at Amarin
Friday August 20 2010
Karl Keegan nominated as CFO of Pharming
Friday August 20 2010
Axel Müller becomes CEO at SkyePharma
Thursday August 19 2010